Company / Interest Expense
Xeris Biopharma Holdings, Inc. Interest Expense History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$26.6M
FY2023
5-year range
$7.2M / $26.6M
FY2020-FY2023
Trend
+270.6%
vs FY2022
Sector context
#17 of 44
Health Care
What the data says
Interest Expense changed +271% YoY in FY2023, a notable deviation from the 3-year average annual change of +79%.
Based on SEC 10-K filings.
$27M in FY2023 with a 3-year CAGR of +35.7%.
Increased from $7M to $27M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +35.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#28 of 44 in Health CareTop 61% of 44This company $26.6M Sector average $291.0M
▼
-90.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +35.7%, indicating consistent growth.
- In FY2023, interest expense increased 270.6% year-over-year.
- Ranks #17 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $26.6M | +270.6% |
| FY2022 | $7.2M | +0.0% |
| FY2021 | $7.2M | -32.6% |
| FY2020 | $10.7M | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026